Roche Diagnostics and Enterprise Ireland launch Incubator Programme

Enterprise Ireland in collaboration with Roche Diagnostics, is delighted to launch the Roche Diagnostics and Enterprise Ireland Incubator Programme 2022

Roche Diagnostics is a multinational company that develops and manufactures in vitro diagnostic solutions to help support clinical decision-making and transform the lives of patients in disease areas including cancer, cardiovascular disease and infectious diseases including COVID-19.

The Roche Diagnostics and Enterprise Ireland Incubator Programme aims to build on work already undertaken by the two organisations to support Irish start-ups and SMEs. Through the incubator, selected companies will be offered the opportunity to take part in a pitch event in Dublin, where one company will be chosen to receive bespoke mentorship from Roche through a 12-week programme. The programme will help them to accelerate their growth, building on Roche’s long-standing expertise in the commercialisation of diagnostics and accelerator know-how.

Irish-owned and headquartered start-ups and Irish university spin-outs with a disruptive diagnostic technology are invited to apply. A webinar on 26 April will launch the programme, where interested parties are invited to attend to learn more regarding the process and how they can apply.

Commenting on the launch of the programme, Finbarr Kenny, Director of Ireland at Roche Diagnostics said, “Roche has a rich heritage in working with Irish-owned companies whom we partner with in providing diagnostic solutions to the Irish healthcare systems in Ireland. We recognise the important role that Enterprise Ireland plays in supporting start-up companies accelerate their innovations that address some of the current as well as future unmet needs, not just in Ireland but globally. We are excited to share our knowledge and experience with Irish start-up companies through this mentoring programme.”

Garrett Murray, Head of the Lifesciences Sector at Enterprise Ireland said, “Enterprise Ireland is very pleased to partner with Roche Diagnostics on this Incubator Programme. Collaboration and partnership are critical to the success of any innovative eco-system. Ireland has a long history of collaboration between companies, higher education institutions and our research and technology centres. This collaborative eco-system is one of the many unique conditions at play in Ireland which have led Irish life sciences companies to be among the most innovative in the world. Supporting the work of Roche Diagnostics on this initiative is very much in line with our strategy to accelerate the development of world-class Irish companies.”

Who should apply

Irish-owned and headquartered start-ups and Irish university spin-outs with a disruptive diagnostic technology are invited to apply. Ideally you are a TRL level 4-6 start-up with innovations in areas such as oncology, cardiovascular, infectious diseases, women’s health and neurodegenerative diseases, with diagnostic solutions that can be applied in a hospital laboratory, hospital point of care, primary care and/or home testing settings.

Events

The Q&A webinar launching the Incubator Programme will take place on Tuesday, 26 April, 2022.

Selected companies will then be invited to attend a pitch event taking place on Monday, 20 June, 2022 at Enterprise Ireland’s Head Office in Dublin. Interested companies are invited to register for the webinar here.

About Roche Diagnostics

Roche Diagnostics is a multinational company that develops and manufactures in vitro diagnostics solutions to help support clinical decision-making and transform the lives of patients. We are defined by the power of our scientific and technological capabilities around the world. Our global network of scientific excellence allows us to introduce and integrate breakthroughs in diagnostic science from across the world into healthcare systems with speed, accuracy and precision. Our portfolio of diagnostic solutions is vast and we are continually innovating. We have over 120 years of history and a track record of innovation and excellence around the world and within the UK and Ireland.